S. Mousa

Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.

F. B. Davis, H. Lin, P. Davis, 2010, The Journal of clinical endocrinology and metabolism.

Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

C. Smith, C. Van Waes, C. Waes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antithrombotics in thrombosis and cancer

S. Mousa, S. Mousa, Shaker A. Mousa, 2005, Hämostaseologie.

Pro- and anti-angiogenic agents.

S. Mousa, A. Bridoux, S. Mousa, 2012, Journal des maladies vasculaires.

Inhibition of angiogenesis by antibody blocking the action of proangiogenic high‐molecular‐weight kininogen

R. Colman, I. Sainz, S. Mousa, 2003, Journal of thrombosis and haemostasis : JTH.

The role of angiogenesis assessment in the prognosis of breast carcinoma and in the evaluation of the therapeutic effect of “ shark care ” drug as an angiogenesis inhibitor

S. Mousa, E. El-Abd, A. Kazem, 2009 .

Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.

F. B. Davis, S. Mousa, P. Davis, 2009, Anticancer research.

Lycopene nanoparticles promotes osteoblastogenesis and inhibits adipogenesis of rat bone marrow mesenchymal stem cells

S. Mousa, M. Badawoud, S. M. Hassan, 2021 .